Nabil Saba
Emory University · Department of Hematology and Medical Oncology, Emory University · Emory University Winship Cancer Institute
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Nabil Saba as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 17:50 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT05814666 · Activity and Safety of Danvatirsen and Pembrolizumab in HNSCCFlamingo Therapeutics NV · terminated · HNSCC · study chair
- Ph3NCT04550260 · Study of Durvalumab Versus Placebo in Combination With Definitive Chemoradiation Therapy in Patient With ESCCAstraZeneca · active not recruiting · Esophageal Squamous Cell Carcinoma · principal investigator
- Ph2NCT00636298 · Study of Cetuximab and Bevacizumab in Cancer of the Esophagus After Failure of Patient's First TherapyEmory University · withdrawn · Esophageal Carcinoma · principal investigator
- Ph2NCT00400205 · Study of Induction Docetaxel, Cisplatin and 5-FluorouracilEmory University · terminated · Squamous Cell Carcinoma, Oral Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 17:50 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Atorvastatin to Reduce Cisplatin-Induced Hearing Loss in Head and Neck Cancer PatientsU01DC020452 · NIDCD · EMORY UNIVERSITY · fiscal years 2023 to 2026 · $397,537 awarded in 2026Same name and institution; not confirmed by an ID
- Winship National Clinical Trials Network Lead Academic Participating SiteUG1CA233247 · NCI · EMORY UNIVERSITY · fiscal years 2021 to 2026 · $920,141 awarded in 2026Same name and institution; not confirmed by an ID
- A Novel genomics-based approach to differentiate HPV-positive and -negative HNCR21CA182661 · NCI · EMORY UNIVERSITY · fiscal years 2014 to 2015 · $169,650 awarded in 2015Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 17:50 UTC. The ranking covers the 200 most relevant of 69 PubMed records, and a shared surname and initials can bring in a namesake. All 69 on PubMed
- Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck.N Engl J Med · 20164,165 citationsRCR 143.4
- 647 citationsRCR 23.1
- Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study.J Clin Oncol · 2017552 citationsRCR 17.8
- 436 citationsRCR 41.2
- 341 citationsRCR 10.5
- Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial.Lancet Oncol · 2015319 citationsRCR 9.3
- 258 citationsRCR 8.9
- Tipifarnib in Head and Neck Squamous Cell Carcinoma With HRAS Mutations.J Clin Oncol · 2021178 citationsRCR 9.3
- Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 study.Blood · 2018169 citationsRCR 5.5
- Ibrutinib-induced lymphocytosis in patients with chronic lymphocytic leukemia: correlative analyses from a phase II study.Leukemia · 2014163 citationsRCR 4.1